Nonmelanomatous Skin Cancer - Pipeline Review, H2 2013


#184891

47pages

Global Markets Direct

$ 2000

In Stock


Global Markets Directs, 'Nonmelanomatous Skin Cancer Pipeline Review, H2 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Nonmelanomatous Skin Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Nonmelanomatous Skin Cancer. Nonmelanomatous Skin Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Nonmelanomatous Skin Cancer.
  • A review of the Nonmelanomatous Skin Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Nonmelanomatous Skin Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Nonmelanomatous Skin Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Nonmelanomatous Skin Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Nonmelanomatous Skin Cancer Overview 6
Therapeutics Development 7
Pipeline Products for Nonmelanomatous Skin Cancer - Overview 7
Pipeline Products for Nonmelanomatous Skin Cancer - Comparative Analysis 8
Nonmelanomatous Skin Cancer - Therapeutics under Development by Companies 9
Nonmelanomatous Skin Cancer - Therapeutics under Investigation by Universities/Institutes 10
Nonmelanomatous Skin Cancer - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Nonmelanomatous Skin Cancer - Products under Development by Companies 13
Nonmelanomatous Skin Cancer - Products under Investigation by Universities/Institutes 14
Nonmelanomatous Skin Cancer - Companies Involved in Therapeutics Development 15
LEO Pharma A/S 15
Genextra S.p.a. 16
Biosceptre International Limited 17
Medicon Pharmaceuticals, Inc 18
Nonmelanomatous Skin Cancer - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Assessment by Therapeutic Class 28
Drug Profiles 30
ingenol mebutate - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
tazarotene - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
DAC-0060 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Dz-13 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Biosceptre Skin Cancer Therapy - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
OXT-328 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
DNA Repair Polypeptides - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Ingenol Mebutate Analogs for Dermatology and Cancer - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Nonmelanomatous Skin Cancer - Recent Pipeline Updates 40
Nonmelanomatous Skin Cancer - Dormant Projects 42
Nonmelanomatous Skin Cancer - Discontinued Products 43
Nonmelanomatous Skin Cancer - Product Development Milestones 44
Featured News & Press Releases 44
Aug 27, 2004: Initiation Of Human Trials 44
Jun 29, 2004: INDs For Peplins Lead Product Filed With FDA 44
Nov 25, 2002: Allergan In-Licenses A Compound For The Treatment Of Non-Melanoma Skin Cancers From Peplin Biotech 45

Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 47
Disclaimer 47

Number of Products under Development for Nonmelanomatous Skin Cancer, H2 2013 7
Number of Products under Development for Nonmelanomatous Skin Cancer - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Number of Products under Investigation by Universities/Institutes, H2 2013 10
Comparative Analysis by Clinical Stage Development, H2 2013 11
Comparative Analysis by Early Stage Development, H2 2013 12
Products under Development by Companies, H2 2013 13
Products under Investigation by Universities/Institutes, H2 2013 14
Nonmelanomatous Skin Cancer - Pipeline by LEO Pharma A/S, H2 2013 15
Nonmelanomatous Skin Cancer - Pipeline by Genextra S.p.a., H2 2013 16
Nonmelanomatous Skin Cancer - Pipeline by Biosceptre International Limited, H2 2013 17
Nonmelanomatous Skin Cancer - Pipeline by Medicon Pharmaceuticals, Inc, H2 2013 18
Assessment by Monotherapy Products, H2 2013 19
Number of Products by Stage and Target, H2 2013 21
Number of Products by Stage and Mechanism of Action, H2 2013 23
Number of Products by Stage and Route of Administration, H2 2013 25
Number of Products by Stage and Molecule Type, H2 2013 27
Number of Products by Stage and Therapeutic Class, H2 2013 29
Nonmelanomatous Skin Cancer Therapeutics - Recent Pipeline Updates, H2 2013 40
Nonmelanomatous Skin Cancer - Dormant Projects, H2 2013 42
Nonmelanomatous Skin Cancer - Discontinued Products, H2 2013 43
Number of Products under Development for Nonmelanomatous Skin Cancer, H2 2013 7
Number of Products under Development for Nonmelanomatous Skin Cancer - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Number of Products under Investigation by Universities/Institutes, H2 2013 10
Comparative Analysis by Clinical Stage Development, H2 2013 11
Comparative Analysis by Early Stage Products, H2 2013 12
Assessment by Monotherapy Products, H2 2013 19
Number of Products by Top 10 Target, H2 2013 20
Number of Products by Stage and Top 10 Target, H2 2013 21
Number of Products by Top 10 Mechanism of Action, H2 2013 22
Number of Products by Stage and Top 10 Mechanism of Action, H2 2013 23
Number of Products by Top 10 Route of Administration, H2 2013 24
Number of Products by Stage and Top 10 Route of Administration, H2 2013 25
Number of Products by Top 10 Molecule Type, H2 2013 26
Number of Products by Stage and Top 10 Molecule Type, H2 2013 27
Number of Products by Top 10 Therapeutic Class, H2 2013 28
Number of Products by Stage and Top 10 Therapeutic Class, H2 2013 29